ADA and cancer: Consistently, data from our earlier human phase I trails for TRAIL-Trimer18 with multiple intra cavity infusions with dosage up to 120 mg which is over 1000X that to be used for S-Trimer subunit vaccine has shown no ADA induced (anti drug antibody) in the cancer patients.